Back to Directory

Ossianix

StevenageEast of England
Founded 2012
VNAR antibody shuttles for brain-targeted biologic therapies

Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier.

Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and bispecific formats for neurological disorders, including a preclinical anti-CD20 programme for progressive multiple sclerosis. Ossianix conducts research at Stevenage Bioscience Catalyst alongside its US operations.

BiopharmaDrug DeliveryNeurologyImmunology
Antibody TherapeuticsNeurodegenerative DiseaseAutoimmune Disease

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page